Tarsus Pharmaceuticals (TARS) Treasury Shares (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Treasury Shares of $721325.0 for Q1 2026, down 62.65% year-over-year from $1.9 million in Q1 2025, and down 58.93% quarter-over-quarter from $1.8 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Treasury Shares (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Treasury Shares history runs 8 years deep, the most recent figure standing at $721325.0 for Q1 2026.
- In Q1 2026, Treasury Shares fell 62.65% year-over-year to $721325.0; the TTM figure through Mar 2026 stood at $721325.0 (down 62.65% YoY), while the FY2025 annual figure was $1.8 million, down 8.3% from the prior year.
- Treasury Shares for Q1 2026 stood at $721325.0, down from $1.8 million in the prior quarter.
- The five-year high for Treasury Shares was $2.0 million in Q1 2024, with the low at $551258.0 in Q4 2022.
- The 5-year median for Treasury Shares is $1.7 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares surged 3095.51% in 2022, then tumbled 63.55% in 2025.
- Tarsus Pharmaceuticals' Treasury Shares stood at $551258.0 in 2022, then surged by 209.97% to $1.7 million in 2023, then increased by 12.09% to $1.9 million in 2024, then decreased by 8.3% to $1.8 million in 2025, then sank by 58.93% to $721325.0 in 2026.
- Business Quant data shows TARS's Treasury Shares at $721325.0 in Q1 2026, $1.8 million in Q4 2025, and $714806.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 1.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.57 Mn |
| Jun 30, 2026 | 1.57 Mn |
| Mar 31, 2026 | 721,325.00 |
| Mar 31, 2026 | 721,325.00 |
| Dec 31, 2025 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 714,806.00 |
| Sep 30, 2025 | 714,806.00 |
| Jun 30, 2025 | 692,623.00 |
| Jun 30, 2025 | 692,623.00 |
| Mar 31, 2025 | 1.93 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.98 Mn |